“I think one important message here is that MTAP is an important novel pathway in carcinogenesis, particularly bladder and urothelial carcinomas,” says Philippe E. Spiess, MD, MS, FRCSC, FACS.
In this video, Philippe E. Spiess, MD, MS, FRCSC, FACS, discusses the takeaways and future research associated with the study, “Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (MTAP) genomic loss,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Spiess is a genitourinary oncologist and assistant chief of surgical services at the Moffitt Cancer Center in Tampa, Florida.
Vobramitamab duocarmazine continues to show promise in mCRPC
May 10th 2024Updated data from the phase 2 TAMARCK study continued to show safety and preliminary efficacy with the B7-H3–targeting antibody-drug conjugate vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer.